| ID Source | ID |
|---|---|
| PubMed CID | 87795 |
| SCHEMBL ID | 11848426 |
| MeSH ID | M0152158 |
| Synonym |
|---|
| ai3-20756 |
| di-n-butyl-2,2-dichlorovinyl phosphate |
| 2,2-dichlorovinyldibutylphosphate |
| phosphoric acid, dibutyl 2,2-dichlorovinyl ester |
| brn 1712889 |
| phosphoric acid, dibutyl 2,2-dichloroethenyl ester |
| einecs 242-584-1 |
| dibutyl 2,2-dichlorovinyl phosphate |
| dibutyl 2,2-dichloroethenyl phosphate |
| di-n-butyldichlorvos |
| di-1-butyl-2,2-dichlorovinyl phosphate |
| 18795-58-9 |
| SCHEMBL11848426 |
| DTXSID4066416 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The induction of central-peripheral distal axonopathy in hens singly dosed with some organophosphorus (OP) compounds, such as di-n-butyl-2,2-dichlorovinyl phosphate (DBDCVP), requires greater than 80% organophosphorylation and subsequent intramolecular rearrangement ("aging") of a protein [neuropathy target esterase (NTE)] in the axon." | ( Progressive deficit of retrograde axonal transport is associated with the pathogenesis of di-n-butyl dichlorvos axonopathy. Lotti, M; Moretto, A; Sabri, MI; Spencer, PS, 1987) | 0.48 |
| " White Leghorn hens were dosed with the neuropathic compounds di-1-butyl-2,2-dichlorovinyl phosphate (dibutyl dichlorvos, DBDCV), tri-o-cresyl phosphate (TOCP), or acrylamide, and regions from brain were fractionated into axolemmal, synaptosomal, and microsomal preparations." | ( Brainstem axolemmal protein phosphorylation in vitro in hens dosed with di-1-butyl-2,2-dichlorovinyl phosphate. Huggins, DJ; Richardson, RJ, 1999) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||